NCT07412886

Brief Summary

55,000 babies are born prematurely in the UK annually. Bleeding in the fluid spaces of the brain (ventricles) is common after prematurity; in England around 450 babies suffer from severe bleeds every year. This is the most important cause of neurological disability after prematurity. Bleeding occurs in the first week of life when the brain is developing rapidly and is most vulnerable to injury. The blood and its breakdown products in the brain fluid (cerebrospinal fluid, CSF) are toxic to the developing brain and cause scarring that blocks the flow and absorption of CSF. In about half these babies, this causes fluid build-up, or post-haemorrhagic ventricular dilatation (PHVD). Current standard treatment of PHVD only drains CSF to reduce pressure inside the brain. Following early results and a successful pilot study at GOSH, we developed an NIHR-funded randomised national trial to analyse the impact of an operation to wash out blood inside the brain using a small endoscope. We will compare standard treatment (fluid drainage alone) with washout plus drainage of fluid. Premature babies typically undergo an MRI scan of the brain at their expected birth time to assess their brain injury, predict the severity of their disability and see what early rehabilitation and treatment they need. In this study we will use new MRI techniques during this scan at GOSH and Alder Hey Hospital to better understand the extent of brain injury in relation to brain structure, function and brain fluid flow. We want to see whether these will show the impact of the washout procedure, tell us about how washout works, and improve prediction of the child's disability and early treatment needs. If successful, we will apply for further funding to extend these techniques to the other centres in the UK and maximise their benefit within the NHS.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
12mo left

Started Feb 2026

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Feb 2026May 2027

First Submitted

Initial submission to the registry

January 29, 2026

Completed
18 days until next milestone

Study Start

First participant enrolled

February 16, 2026

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 17, 2026

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

February 17, 2026

Status Verified

February 1, 2026

Enrollment Period

1.2 years

First QC Date

January 29, 2026

Last Update Submit

February 9, 2026

Conditions

Keywords

intraventricular hemorrhagepost-hemorrhagic ventricular dilatationmagnetic resonance imagingcognitive development

Outcome Measures

Primary Outcomes (1)

  • Feasibility

    Number (percentage) of patients completing total scan protocol

    At the time of scan (18 months)

Secondary Outcomes (2)

  • Scan quality

    At end of study period (18 months)

  • Correlation to developmental outcomes

    At end of study (18 months)

Study Arms (1)

Advanced MRI Sqeuences

EXPERIMENTAL

We will acquire advanced MRI sequences including diffusion tensor imaging (DTI), quantitative susceptibility mapping (QSM) and resting-state functional MRI (rs-fMRI)

Diagnostic Test: Advanced MRI

Interventions

Advanced MRIDIAGNOSTIC_TEST

We will acquire advanced MRI sequences including diffusion tensor imaging (DTI), quantitative susceptibility mapping (QSM) and resting-state functional MRI (rs-fMRI)

Advanced MRI Sqeuences

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Alder Hey Children's Hospital

Liverpool, United Kingdom

Location

Great Ormond Street Hospital for Children

London, United Kingdom

Location

Central Study Contacts

Kristian Aquilina, PhD, FRCS (SN)

CONTACT

Aswin Chari, PhD, FRCS (SN)

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: Prospective cohort study at 2 centres over 18 months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 29, 2026

First Posted

February 17, 2026

Study Start

February 16, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

February 17, 2026

Record last verified: 2026-02

Locations